CFO transition is orderly with a qualified replacement and no accounting red flags. The reaffirmed FY2026 guidance of $74M-$78M revenue (50% growth is the key signal — watch for upcoming CMS reimbursement catalyst on Oct 1 and product launches for aprevo Lumbar Bi-lateral and corra cervical. Monitor next 10-Q for revenue trajectory vs guidance.
Price Chart
Executive Summary
Carlsmed announced the departure of CFO Leo Greenstein (effective Sept 25, 2026) and the appointment of Richard Heppenstall as his replacement, effective Sept 28, 2026. The company also reaffirmed its FY2026 revenue guidance of $74M-$78M (50% YoY growth at midpoint). This is a routine CFO succession with no accounting disagreements or red flags, and the reaffirmed guidance provides stability.
Key Facts
- CFO Leo Greenstein departed effective Sept 25, 2026; departure not related to any accounting or internal control disagreement
- Richard Heppenstall appointed CFO effective Sept 28, 2026; previously EVP/CFO of ZimVie Inc. until its acquisition in Oct 2025
- Heppenstall receives $500,000 base salary, 60% target annual bonus, $1.4M stock option grant (180,137 shares at $14.18/sh), and $1.4M RSU grant (89,286 RSUs)
- Greenstein receives $500,000 severance (12 months base salary), pro-rated 2026 bonus, 12 months COBRA, and accelerated vesting on certain equity awards
- Company reaffirms FY2026 revenue guidance of $74M to $78M, representing 50% growth over 2025 at the midpoint
- New aprevo Lumbar CMS reimbursement effective Oct 1, 2026; upcoming launches of aprevo Lumbar Bi-lateral and corra cervical procedures
Financial Impact
No financial impact from the CFO change itself; FY2026 revenue guidance reaffirmed at $74M-$78M (50% YoY growth at midpoint). Severance cost of $500,000 cash plus equity acceleration for departing CFO.
Risk Factors
- CFO transition execution risk during a key product launch period
- New CFO's relocation transition to Southern California may cause short-term distraction
- Guidance reaffirmation provides a floor but no upside surprise — any miss would be a negative surprise
Investment Themes
Documents Analyzed
This report is based on 11 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001794546-26-000020 |
| Document: carl-ex10_5.htm | 0001794546-26-000020 |
| Document: carl-ex10_2.htm | 0001794546-26-000020 |
| Document: carl-ex10_1.htm | 0001794546-26-000020 |
| Document: carl-20260924.htm | 0001794546-26-000020 |
| Document: carl-ex10_6.htm | 0001794546-26-000020 |
| Document: carl-ex10_4.htm | 0001794546-26-000020 |
| Document: carl-ex99_1.htm | 0001794546-26-000020 |
| Document: 0001794546-26-000020-index-headers.html | 0001794546-26-000020 |
| Document: 0001794546-26-000020-index.html | 0001794546-26-000020 |
| Document: 0001794546-26-000020.txt | 0001794546-26-000020 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 144 | $13.85 | awaiting T+20 | — | $14.91 (+7.65%) |
Sep 30, 2026 26d ago | 8-K | $14.07 | awaiting T+20 | — | $14.91 (+5.97%) |
Sep 28, 2026 28d ago | Press Release | $14.18 $14.91 | ▲ +5.15% | ▲ +5.18% | $14.91 (+5.15%) |
Sep 15, 2026 5w ago | Insider Buy | $15.31 $14.47 | ▼ −5.49% | ▼ −8.66% | $14.91 (−2.61%) |
Aug 24, 2026 9w ago | EFFECT | $15.80 $15.42 | ▼ −2.41% | ▼ −3.72% | $14.91 (−5.63%) |
Jul 22, 2026 13w ago | Press Release | $11.00 $16.50 | ▲ +50.00% | ▲ +46.69% | $14.91 (+35.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers